PC-9Homo sapiens (Human)Cancer cell line
Also known as: PC-9S1, PC-9/S1, PC9
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_B260 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Lymph node[UBERON:UBERON_0000029] |
Donor Information
| Age | 45 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | asian |
Disease Information
| Disease | Lung adenocarcinoma |
|---|---|
| Lineage | Lung |
| Subtype | Lung Adenocarcinoma |
| OncoTree Code | LUAD |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-000779_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Arg248Gln (c.743G>A) | Unspecified | Somatic mutation acquired during proliferation | PubMed=20575032 |
| MutationSimple | EGFR | p.Glu746_Ala750del (c.2235_2249del15) | Unspecified | - | from parent cell line PC-9 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Potential utility of a 4th-generation EGFR-TKI and exploration of resistance mechanisms -- an in vitro study.
Mitsudomi T., Tsutani Y.
Biomedicines 12:1412.1-1412.13(2024).
Genetic diversity among the present Japanese population: evidence from genotyping of human cell lines established in Japan.
Kasai F., Fukushima M., Miyagi Y., Nakamura Y.
Hum. Cell 37:944-950(2024).
The cancer SENESCopedia: a delineation of cancer cell senescence.";
Leite de Oliveira R., Wessels L.F.A., Bernards R.
Cell Rep. 36:109441.1-109441.22(2021).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Chemistry-first approach for nomination of personalized treatment in lung cancer.
Posner B.A., Minna J.D., Kim H.S., White M.A.
Cell 173:864-878.e29(2018).
Phosphoproteomics reveals HMGA1, a CK2 substrate, as a drug-resistant target in non-small cell lung cancer.
Chen Y.-J.
Sci. Rep. 7:44021-44021(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Rapid high-pH reverse phase stagetip for sensitive small-scale membrane proteomic profiling.
Chen Y.-J.
Anal. Chem. 87:12016-12023(2015).
Mining missing membrane proteins by high-pH reverse-phase stagetip fractionation and multiple reaction monitoring mass spectrometry.
Nesvizhskii A.I., Sung T.-Y., Chen Y.-J.
J. Proteome Res. 14:3658-3669(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance.
Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z.-M., Pao W.
Genome Res. 23:1434-1445(2013).
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Igishi T., Burioka N., Nanba E., Shimizu E.
Cancer Biol. Ther. 13:369-378(2012).
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Cancer Sci. 101:1891-1896(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Identification of ribosomal protein L19 as a novel tumor antigen recognized by autologous cytotoxic T lymphocytes in lung adenocarcinoma.
Ichiki Y., Yasuda M., Uramoto H., Hanagiri T., Yasumoto K.
Cancer Sci. 101:46-53(2010).
A gene-alteration profile of human lung cancer cell lines.";
Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
Hum. Mutat. 30:1199-1206(2009).
Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro.
Yasumoto K.
Cancer Sci. 98:1048-1054(2007).
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Takada M., Fukuoka M., Nakagawa K.
Cancer Res. 67:2046-2053(2007).
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.
Cancer Res. 65:7276-7282(2005).
Altered expression and function of beta1 integrins in a highly metastatic human lung adenocarcinoma cell line.
Kudoh S.
Int. J. Oncol. 17:1187-1194(2000).
Mutation and expression of the DCC gene in human lung cancer.";
Yokota J.
Neoplasia 2:300-305(2000).
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes.
Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.
Int. J. Oncol. 15:927-934(1999).
Variable expression on lung cancer cell lines of HLA-A2-binding MAGE-3 peptide recognized by cytotoxic T lymphocytes.
Shibuya A., Tsuji T., Sekiguchi S., Nakayama E.
Int. J. Oncol. 12:1103-1109(1998).
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Itoh K.
Cell. Immunol. 177:176-181(1997).
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
Cell. Immunol. 175:101-110(1997).
Gene analysis of K-, H-ras, p53, and retinoblastoma susceptibility genes in human lung cancer cell lines by the polymerase chain reaction/single-strand conformation polymorphism method.
Kashii T., Mizushima Y., Monno S., Nakagawa K., Kobayashi M.
J. Cancer Res. Clin. Oncol. 120:143-148(1994).
Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9, PC-13 and PC-14) and how they influence the results of test for chemosensitivity to cisplatin in the human tumor clonogenic assay.
Hoshi A., Chen K.-M., Hamburger A.W.
Jpn. J. Clin. Oncol. 15:637-644(1985).
Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Saijo N.
Cancer Chemother. Pharmacol. 27:263-270(1991).
Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor.
Nomoto K.
Cancer Res. 52:775-781(1992).
Thromboplastic and fibrinolytic activities of cultured human cancer cell lines.
Yasumoto K.
Br. J. Cancer 39:15-23(1979).
Analysis of LDH isoenzyme patterns in cell lines of the small cell carcinoma (lung) and retinoblastoma.
Higuchi H., Uei Y.
Nihon Rinsho Saibo Gakkai Zasshi 24:451-456(1985).